NAUT

Nautilus Biotechnolgy, Inc. (NAUT) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Financial Distress Liquidity Risk

Very strong near-term liquidity with a current ratio of 10.14x and cash ratio of 1.52x.

Net debt remains low relative to EBITDA, with netDebtToEBITDATTM at -0.27x.

Net current asset value is positive at $55.2M, supporting balance-sheet resilience.

Profitability Cash Burn Risk

TTM margins remain deeply negative, with gross margin at -9.2% and net margin at -297.5%.

Operating cash flow and free cash flow are both negative, with freeCashFlowYieldTTM at -42.4%.

Returns on capital remain weak, including ROIC at -39.5% and ROE at -37.6%.

Valuation Dilution Risk

Valuation remains difficult to anchor on earnings or cash flow because TTM earnings and free cash flow are negative.

Price-to-book is 0.93x and price-to-sales is extremely elevated at 644.18x, reflecting a highly speculative revenue base.

Stock-based compensation remains meaningful at 28.9% of revenue, which can pressure per-share economics.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nautilus Biotechnolgy, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →